Baxter Net Long-Term Debt 2010-2025 | BAX
Baxter annual/quarterly net long-term debt history and growth rate from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Baxter net long-term debt for the quarter ending March 31, 2025 was $-3.125B, a 20733.33% increase year-over-year.
- Baxter net long-term debt for the twelve months ending March 31, 2025 was $-7.433B, a 153.69% increase year-over-year.
- Baxter annual net long-term debt for 2024 was $-2.657B, a 0.87% increase from 2023.
- Baxter annual net long-term debt for 2023 was $-2.634B, a 176.1% increase from 2022.
- Baxter annual net long-term debt for 2022 was $-0.954B, a 110.23% decline from 2021.
| Baxter Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $-2,657 |
| 2023 | $-2,634 |
| 2022 | $-954 |
| 2021 | $9,326 |
| 2020 | $704 |
| 2019 | $1,883 |
| 2018 | $N/A |
| 2017 | $665 |
| 2016 | $260 |
| 2015 | $3,082 |
| 2014 | $-988 |
| 2013 | $3,096 |
| 2012 | $1,015 |
| 2011 | $483 |
| 2010 | $91 |
| 2009 | $673 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $14.656B | $10.636B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $218.924B | 25.68 |
| Boston Scientific (BSX) | United States | $159.425B | 38.08 |
| Stryker (SYK) | United States | $153.031B | 32.00 |
| EssilorLuxottica (ESLOY) | France | $136.054B | 0.00 |
| Medtronic (MDT) | Ireland | $118.007B | 16.73 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.909B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.800B | 25.00 |
| ResMed (RMD) | United States | $40.084B | 30.11 |
| GE HealthCare Technologies (GEHC) | United States | $35.372B | 16.79 |
| Agilent Technologies (A) | United States | $33.937B | 22.12 |
| Terumo (TRUMY) | Japan | $25.318B | 32.88 |
| Koninklijke Philips (PHG) | Netherlands | $24.891B | 17.47 |
| Insulet (PODD) | United States | $20.174B | 79.19 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.257B | 12.37 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.945B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.996B | 24.34 |
| Lantheus Holdings (LNTH) | United States | $5.072B | 12.79 |
| Perrigo (PRGO) | Ireland | $3.866B | 9.80 |
| Prestige Consumer Healthcare (PBH) | United States | $3.792B | 16.94 |
| Haemonetics (HAE) | United States | $3.582B | 16.32 |
| Envista Holdings (NVST) | United States | $3.517B | 29.23 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.175B | 23.41 |
| LeMaitre Vascular (LMAT) | United States | $1.856B | 41.49 |
| QuidelOrtho (QDEL) | United States | $1.799B | 12.37 |
| AtriCure (ATRC) | United States | $1.526B | 0.00 |
| Acuren (TIC) | United States | $1.435B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.301B | 13.20 |
| Green Thumb Industries (GTBIF) | United States | $1.217B | 27.38 |
| Phibro Animal Health (PAHC) | United States | $1.208B | 15.44 |
| Neogen (NEOG) | United States | $1.098B | 14.06 |
| BioLife Solutions (BLFS) | United States | $1.074B | 0.00 |
| InMode (INMD) | Israel | $0.944B | 9.51 |
| Kestra Medical Technologies (KMTS) | United States | $0.859B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.838B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.741B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.667B | 0.00 |
| Owens & Minor (OMI) | United States | $0.637B | 5.28 |
| Valneva SE (VALN) | France | $0.622B | 0.00 |
| Evolus (EOLS) | United States | $0.618B | 0.00 |
| CeriBell (CBLL) | United States | $0.569B | 0.00 |
| ZimVie (ZIMV) | United States | $0.523B | 23.77 |
| Surmodics (SRDX) | United States | $0.464B | 0.00 |
| SNDL (SNDL) | Canada | $0.420B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.317B | 11.65 |
| Sanuwave Health (SNWV) | United States | $0.315B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.314B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.312B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.298B | 0.00 |
| Quanterix (QTRX) | United States | $0.284B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.274B | 81.33 |
| Viemed Healthcare (VMD) | United States | $0.255B | 21.53 |
| OraSure Technologies (OSUR) | United States | $0.247B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.243B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.240B | 0.00 |
| Biote (BTMD) | United States | $0.232B | 6.52 |
| Brainsway (BWAY) | Israel | $0.225B | 59.45 |
| Omeros (OMER) | United States | $0.224B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.217B | 0.00 |
| Organigram Global (OGI) | Canada | $0.208B | 0.00 |
| High Tide (HITI) | Canada | $0.196B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.189B | 15.39 |
| TriSalus Life Sciences (TLSI) | United States | $0.178B | 0.00 |
| Exagen (XGN) | United States | $0.156B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.151B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.127B | 15.65 |
| TerrAscend (TSNDF) | Canada | $0.116B | 0.00 |
| MacroGenics (MGNX) | United States | $0.114B | 0.00 |
| Jin Medical (ZJYL) | China | $0.110B | 0.00 |
| Safety Shot (SHOT) | United States | $0.105B | 0.00 |
| Fonar (FONR) | United States | $0.101B | 12.98 |
| Quipt Home Medical (QIPT) | United States | $0.097B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.087B | 0.00 |
| Apyx Medical (APYX) | United States | $0.086B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| Zynex (ZYXI) | United States | $0.076B | 0.00 |
| Agape ATP (ATPC) | $0.074B | 0.00 | |
| InterCure (INCR) | Israel | $0.070B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.063B | 0.00 |
| United-Guardian (UG) | United States | $0.044B | 15.21 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| Nephros (NEPH) | United States | $0.037B | 50.43 |
| Allurion Technologies (ALUR) | United States | $0.024B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |